Surrozen Presents Preliminary Results Of Phase 1a Study Of SZN-043 In Liver Cirrhosis Patients At EASL 2024

SZN-043 is a novel biotherapeutic shown to potentiate Wnt signaling and induce proliferation of hepatocytes in preclinical models

Treatment with SZN-043 in the Phase 1a trial was safe and well tolerated in healthy volunteers and patients with a history of liver cirrhosis

Phase 1a trial of SZN-043 demonstrated evidence of target engagement and Wnt-pathway mediated pharmacodynamic effects in the liver

Enrollment is ongoing in Phase 1b study in severe alcohol-associated hepatitis